Edinburgh MedTech Firm Trogenix Secures £70M for Cancer Therapies
Edinburgh-based MedTech firm Trogenix has secured £70 million in a Series A funding round, led by IQ Capital. The investment will accelerate the development of the company's next-generation cancer therapies targeting aggressive solid tumours.
Trogenix, spun out from the University of Edinburgh and backed by 4BIO Capital, aims to kill cancer cells and boost the immune system while leaving healthy tissue unharmed. The company's lead programme in glioblastoma is set to enter clinical trials in Q1 2026, with first patient dosing expected during this period.
The funding will advance Trogenix's lead programme in glioblastoma and a follow-on programme in colorectal cancer liver metastases. It will also support the expansion of the company's pipeline in liver and lung cancers, and the continued development of its proprietary Odysseus platform. CEO Ken Macnamara expressed that the investment will accelerate the company's lead programmes and enhance the Odysseus platform. Max Bautin, co-founder and managing partner at IQ Capital, expressed confidence in Trogenix's science, management team, and roadmap for delivery.
Trogenix's £70 million Series A funding round, led by IQ Capital and including 4BIO Capital, will fuel the development of curative therapies for aggressive cancers. The company's lead glioblastoma programme is on track to enter clinical trials in early 2026, marking a significant milestone in its mission to improve cancer treatment outcomes.
Read also:
- Abu Dhabi initiative for comprehensive genetic screening, aiming to diagnose over 800 conditions and enhance the health of future generations in the UAE.
- Elderly shingles: Recognizing symptoms, potential problems, and available treatments
- Exploring the Reasons, Purposes, and Enigmas of Hiccups: Delving into Their Origins, Roles, and Unsolved Aspects
- Various forms of cataracts include nuclear, pediatric, traumatic, and additional types
